Quarterly Revenues Include Revenue Recognition. Lineage Cell Reported a loss of $6.8 million or $(0.04) per share, in-line with our estimate of $4.6 million or $(0.03) per share. Progress on the OpRegen collaboration with Roche/Genentech accounted for revenue of $4.1 million out of $4.6 million total revenues. The company ended the quarter with $72.0 million in cash.OpRegen Progress Allowed Revenue Recognition. The OpRegen collaboration with Roche/Genentech brought in net fees of about $29 million, after allocation of amounts due to its licensors. The amount is being amortized over the course of the agreement, with revenue recognized as obligations under the agreement are met. Lineage recognized $4.1 million under the agreement in 2Q22 and a total of $9.0 million for the year to date. This reflects progress on Chemistry and Manufacturing Controls (CMC), technology transfers, and manufacturing milestones. Read More >>